# Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

> **NCT02941848** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 60 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HGP0816
- **DRUG:** HGP1404
- **DRUG:** HCP1306

## Key facts

- **NCT ID:** NCT02941848
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2014-12
- **Final completion:** 2015-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941848, "Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02941848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*